Datasets:

Kira-Asimov

/

gender_clinical_trial

like 2

NCT00000432

Inclusion Criteria: Ferry passengers traveling to Nantucket Island Exclusion Criteria: Foreign (non-U.S.) residence

All

NCT00000433

Inclusion Criteria: Diagnosis of Ankylosing spondylitis Acceptable stable treatments during study: oral glucocorticoids (less than or equal to 10 mg/d) and/or NSAIDs at recommended doses and/or one of the following options: methotrexate (less than or equal to 20.0 mg/week); sulfasalazine (less than or equal to 3 grams/d); azathioprine (less than or equal to 2 mg/kg/d); methotrexate and sulfasalazine combination at doses listed above; 6-mercaptopurine (less than or equal to 1.5 mg/kg/d) Exclusion Criteria: Diagnosis of psoriatic arthritis, inflammatory bowel disease, reactive arthritis, or Behýet disease Significant medical problems, such as diabetes mellitus History of active or recurrent infections Complete ankylosis of the entire spine

All

NCT00000434

Inclusion Criteria: 60 years of age or older Presence of osteoarthritis of the lower extremities with an American College of Rheumatology functional class rating of I, II, or III No other contraindication from a personal physician for participation in the fitness walking Lack of moderate-to-severe cognitive impairment as assessed by the Short Portable Mental Status Questionnaire Exclusion Criteria: Under 60 years of age Lack of osteoarthritis of the lower extremities Contraindication from a personal physician for participation in fitness walking Presence of moderate-to-severe cognitive impairment as assessed by the Short Portable Mental Status Questionnaire Steroid injections in either hip or knee within the previous 6 months Uncomplicated knee or hip surgery within previous year Complicated knee or hip surgery within previous year Plans for total knee or hip replacement within the next year Rheumatoid arthritis or other systemic inflammatory arthritis Diabetes that is not under control Current participation in a structured aerobic exercise program

All

NCT00000435

Inclusion Criteria: Active rheumatoid arthritis as defined by the revised American College of Rheumatology (ACR) 1987 criteria. Evidence of active disease will be based on at least six swollen or nine tender joints. Diagnosis of rheumatoid arthritis of less than 5 years Reactivity to dnaJ Agree to use acceptable methods of contraception Able to understand and sign informed consent Exclusion Criteria: Patients taking more 7.5 mg of prednisone or disease modifying agents other than hydrochloroquine or sulfasalazine (i.e., gold, penicillamine, azathioprine, cyclophosphamide, methotrexate, cyclosporine, or anti-TNF agents) Serum creatinine greater than 1.5 mg/dl SGOT less than SGPT Alkaline phosphatase greater than 2 times age/sex adjusted normal values Hematocrit of less than 30 Platelets less than 130,000 History of lymphoma Any active malignancy or cancer requiring treatment in the last 5 years, except for nonmelanoma skin cancers and carcinoma of the cervix in situ Medical or psychiatric condition or active serious infection Pregnant or breastfeeding

All

NCT00000436

Inclusion Criteria: Patients who are 65 years of age and older, and who have been admitted for a hip fracture to the Fracture Service at New York Presbyterian Hospital. Exclusion Criteria: Patients who are unable to give informed consent on the 4th or 5th day after surgery. Patients whose hip fracture is due to underlying disease, secondary to malignancy (cancer). Patients who do not speak English. Patients for whom exercise is contraindicated or whose physicians believe that exercise is contraindicated. Patients who do not have access to a telephone or cannot be reached by telephone. Patients and physicians who refuse to participate or who intend to relocate upon discharge.

All

NCT00000437

Inclusion Criteria: Meets criteria for alcohol dependence and nicotine dependence. Expresses a desire to cut down or stop drinking and smoking. Exclusion Criteria: Currently meets criteria for dependence on substances other than alcohol and nicotine. Any history of opiate dependence or evidence of current opiate use. Significant medical disorders that will increase potential risk or interfere with study participation. Liver function tests more than 3 times normal or elevated bilirubin. Females who are pregnant, nursing, or not using a reliable method of birth control. Meets criteria for a major psychiatric disorder and is in need of or currently undergoing drug therapy. Inability to understand and/or comply with the provisions of the protocol and consent form. Treatment with an investigational drug during the previous month. Chronic treatment with any narcotic-containing medications during the previous month. Sensitivity to drug as evidenced by adverse drug experiences especially with narcotic- containing analgesics or opioid antagonists. Current treatment with disulfiram (Antabuse) or nicotine replacement therapy. More than 6 weeks of abstinence.

All

NCT00000438

Inclusion Criteria: Meets criteria for alcohol dependence. Committed to alcohol abstinence as a treatment goal. Individuals will be required to identify two family members or close friends who are knowledgeable about their location, drinking behavior, and psychosocial status. Exclusion Criteria: Meets criteria for any other psychoactive substance use disorder (excluding nicotine and caffeine). Meets criteria for a major psychiatric disorder and are in need of or currently undergoing pharmacotherapy. Females who are pregnant, lactating, or not using a reliable method of contraception. Currently experiencing a serious medical condition that would place them at risk or interfere with study participation. Experiencing acute hepatitis or liver failure or whose liver function test is more than 3 times normal. Have a history of severe allergies, multiple adverse drug reactions or known allergy to naltrexone. Vocabulary below the 5th grade reading level. Abnormal MRI scan. HIV infection due to the neurological sequelae. Significant central nervous system diseases. Seizure disorder or history of closed head trauma. Neuroendocrine disorders. Treatment with opiates within the last six months.

All

NCT00000439

Inclusion Criteria: Meets the criteria for alcohol dependence with comorbid bipolar disorder. Agreement to participate in outpatient treatment. Ability to tolerate lithium carbonate and be randomized to receive sodium valproate or placebo. Stable living situation. Ability to provide informed consent. Exclusion Criteria: Psychiatric conditions including schizophrenia, schizoaffective disorder, any non-bipolar psychotic disorder, unipolar major depression, mental retardation, or signs of impaired cognitive functioning. Neurological conditions including epilepsy, history of brain injury, encephalitis, or any organic brain syndrome or focally abnormal electroencephalographic examination. Medical conditions including severe cardiac, liver, kidney, endocrine, hematologic, other impairing or unstable medical condition or impending surgery. Persistent elevation of liver function enzymes indicating active liver disease. Pregnancy or not using an acceptable contraceptive method. Inability to read or understand study forms; agree to informed consent. Impending incarceration or a mandate to attend treatment by the legal system for an alcohol use disorder. The presence of either/or cocaine dependence, opioid dependence, and intravenous drug use.

All

NCT00000440

Inclusion Criteria: Meets the criteria for alcohol dependence. Abstinent from alcohol for a period of at least 5 days and not greater than 30 days. Able to read English and complete study evaluations. A stable residence and a telephone to ensure that subjects can be located during the study. Exclusion Criteria: Currently meets criteria for substance abuse or dependence with the exception of nicotine dependence. Current use of disulfiram (Antabuse) or a MAO Inhibitor. Psychotic or otherwise severely psychiatrically disabled (i.e., depressed, suicidal, current mania). Major depression at the time of assessment. Previous treatment with naltrexone (Revia) for alcohol dependence. Significant underlying medical conditions such as cerebral, renal, thyroid, or cardiac disease. Abstinent longer than 30 days prior to admission to program. Hepatocellular disease or elevated bilirubin levels. Females who are pregnant, nursing, or not using a reliable method of birth control.

All

NCT00000441

Inclusion Criteria: Meets criteria for alcohol dependence and uncomplicated alcohol withdrawal syndrome. Ability to provide informed consent, complete self-rating questionnaires, and respond to structured clinician-rated instruments. Must live within 50 miles or one hour of the study site and have reliable transportation to the site. Must have a significant other who will provide a collateral report, attend outpatient visits, and be available by telephone. Subjects must be medically stable. Must have a clinical withdrawal assessment prior to study. Exclusion Criteria: Meets criteria for any other substance dependence syndrome other than alcohol dependence or marijuana abuse. Use of other illicit psychoactive substances (except marijuana) in the last 7 days. Use of pharmaceutical agents within the last 14 days that are known to lower the seizure threshold, augment or decrease the alcohol withdrawal syndrome. History of status epilepticus or two or more seizures occurring within 24- hour period during a previous alcohol withdrawal or other forms of epilepsy. Current major depressive illness, dementia, suicidal or homicidal ideation, or past or present schizophrenia. Acute medical instability as characterized by hepatic encephalopathy, past or present severe liver failure. Diabetes requiring insulin, or severe renal disease. Pregnant females. High blood pressure. Individuals with vomiting who cannot take oral medications at beginning of study or whose vomiting can be controlled only with antiemetic medication. High white blood count, or liver function test that is 3 times higher than normal. Known hypersensitivity or previous adverse reaction to carbamazepine, lorazepam, or other benzodiazepines. Any relevant ECG abnormality which might require hospitalization or greatly interfere with safety during outpatient withdrawal. History of severe gastrointestinal (GI) disease which might render absorption of the medication difficult or produce medical instability of the patient during detoxification which would include active peptic ulcer disease, ulcerative colitis, regional ileitis, or evidence by history or physical examination of GI bleeding. Familial tremor or other neurological condition, determined by history, known to produce tremor. Unable to provide a written informed consent.

All

NCT00000442

Inclusion Criteria: Meets criteria for alcohol dependence. Abstinent from alcohol for a period of at least 3 days prior to beginning of study. Able to read English and complete study evaluations. Females who are postmenopausal, have had surgical sterilization, or use reliable means of birth control. Exclusion Criteria: Meets criteria for dependence on a psychoactive substance other than alcohol and nicotine and/or cannabis. Prior history of opioid dependence. Regular use of psychoactive drugs including anxiolytics and antidepressants. Prior treatment with naltrexone. Current use of disulfiram. Psychotic or otherwise severely psychiatrically disabled (e.g., suicidal, current mania). Significant underlying medical conditions such as hepatic, cerebral, renal, thyroid, or cardiac disease. Abstinent longer than 28 days prior to randomization.

All

NCT00000443

Inclusion Criteria: Meet criteria for alcohol dependence. Subjects with early onset alcoholism must also have a diagnosis of antisocial personality disorder. Understand the requirements of the study and be able to complete the questionnaires and rating scales. Exclusion Criteria: Current diagnosis of substance dependence or self-report of having used narcotics (opiates, cocaine, amphetamine-like substances, and hallucinogens) in the 30 day period prior to study. Positive urine drug screen test for narcotics, barbiturates, or benzodiazepines. Receiving current psychotropic medications. Current history of other psychiatric disorders excluding nicotine dependence. Hepatocellular disease. Pregnant females.

All

NCT00000444

Inclusion Criteria: Meets criteria for alcohol use disorder and other drug dependence. Complete first week of alcohol treatment program. Current cigarette smoker (more than 5 cigarettes/day, smoking more than 1 year). Exclusion Criteria: Lifetime diagnosis of an excluding psychiatric disorder: bipolar disorder, schizophrenia or other psychotic disorder, panic disorder with or without agoraphobia, obsessive-compulsive disorder, generalized anxiety disorder, eating disorder, post- traumatic stress disorder, antisocial personality disorder, or borderline personality disorder. Unable to participate in protocol due to functional deficits or severe depression. Suicidal or homicidal ideation. Current use of disulfiram (Antabuse) or naltrexone (Revia). Current use of pipes, cigars, or smokeless tobacco and unwillingness to stop. Lives more than 100 miles from alcohol treatment facility. No telephone.

All

NCT00000445

Inclusion Criteria: Meets criteria for alcohol dependence (within the past 3 months). Meets criteria for another substance use disorder (except narcotic dependence) but must identify alcohol as the primary substance of abuse. Must be able to provide an informed consent. Consent to random assignment and be willing to commit to possible medication treatment and research follow-up. Must be eligible for treatment at the Dorchester Alcohol and Drug Commission. Exclusion Criteria: Meets criteria for opiate dependence. Clinically significant medical problems such as collagen-vascular disease, cardiovascular, renal, gastrointestinal or endocrine problem that would impair participation or limit medication ingestion. Hepatocellular disease. Women who are pregnant, nursing, or not practicing an effective means of birth control. Currently being prescribed naltrexone. Known sensitivity or allergy to naltrexone.

All

NCT00000446

Inclusion Criteria: Meets criteria for alcohol abuse or dependence and post-traumatic stress disorder. Laboratory tests for blood and urinalysis must be within normal limits. Must be clearly motivated to obtain benefit from treatment and keep appointments for study visits and therapy sessions. Females who use an acceptable method of birth control, are sterilized, or are at least 2 years post-menopausal. Exclusion Criteria: Have a diagnosis of schizophrenia, bipolar affective disorder, dissociative identity disorder, eating disorder, substance dependence in the last 60 days. Currently suicidal. Medical reasons not to receive drug therapy. Allergy or hypersensitivity to selective serotonin inhibitor antidepressants. Significant hematological, endocrine, cardiovascular, renal, hepatic, neurological, or gastrointestinal disease. Liver function test greater than 2 times the normal level Require ongoing therapy with another psychoactive drug during the study period. Females who are pregnant or lactating.

All

NCT00000447

Inclusion Criteria: Meets criteria for alcohol and nicotine dependence. Individuals will be outpatients with alcohol and nicotine dependence who have completed detoxification (medicated or nonmedicated) within the past 48-120 hours. Smoking no less than 10 cigarettes/day and no greater than 50 cigarettes/day. Motivated to quit smoking. Willing and able to participate in the 12 week outpatient treatment. Acceptable health. Able to provide a collateral informant. Willing to be followed for 6 months after treatment ends. Willing and able to provide the names of three family members or friends to aid in locating participants for follow-up. Exclusion Criteria: Current diagnosis of dependence on other substances except nicotine and alcohol. Having moderately severe or severe alcohol withdrawal symptoms. Recent (less than 48 hours) evidence of hazardous drinking (more than 2 drinks/day for females; 3 drinks/day for males). History of opioid abuse. Recent use of cocaine. Not desiring to quit smoking. Recent past or current pharmacotherapy involving naltrexone or transdermal nicotine systems. History of psychosis. Current suicidality, homicidally or psychiatric symptoms requiring other medications. Presence of medical abnormalities that contraindicate naltrexone or nicotine replacement therapy. Current treatment with psychotropic medications. Pregnancy or nursing for female patients. Inability or unwillingness to participate in the 12-week outpatient treatment.

All

NCT00000448

Inclusion Criteria: Meets criteria for alcohol dependence. Abstinent from alcohol for a period of at least 5 days. Able to read English and complete study evaluations. A stable residence and a telephone to ensure that subjects can be located during the study. Exclusion Criteria: Meets criteria for dependence on another psychoactive substance besides alcohol or nicotine. Regular use of psychoactive drugs except antidepressants. Current use of disulfiram (Antabuse). Psychotic or otherwise severely psychiatrically disabled. Significant underlying medical conditions such as cerebral, renal, thyroid, or cardiac pathology. Abstinent longer than 30 days prior to admission to program. Hepatocellular disease or elevated bilirubin levels. Individuals with present history of opiate abuse or who require the use of opioid analgesics. Women who are pregnant, nursing, or not using a reliable method of birth control. Women who are significantly overweight or significantly underweight.

Female

NCT00000449

Inclusion Criteria: Meets criteria for alcohol dependence. Exclusion Criteria: Current diagnosis of dependence on other substances except nicotine. A history of psychosis or current psychotic symptoms. Current suicidality, homocidality, or psychiatric symptoms that require additional medication. Current use of disulfiram (Antabuse). Evidence of significant cerebral, renal, thyroid, or cardiac disease. History of opioid abuse in the previous year. History of cirrhosis, hepatocellular disease, or elevated bilirubin. Females who are pregnant, nursing, or not using a reliable method of birth control.

All

NCT00000450

Inclusion Criteria: Meets criteria for alcohol dependence. Expresses a desire to cut down or stop drinking. Exclusion Criteria: Currently meets criteria for dependence on substances other than alcohol. History of opiate dependence or evidence of current opiate use. Significant medical disorders that will increase potential risk or interfere with study participation. Liver function tests more than 3 times normal or elevated bilirubin. Female patients who are pregnant, nursing, or not using a reliable method of birth control. Inability to understand and provide a consent form. Treatment with an investigational drug during the previous month. Prior treatment with naltrexone. Chronic treatment with any narcotic-containing medications during the previous month. Sensitivity to naltrexone as evidenced by adverse drug experiences especially with narcotic containing analgesics or opioid antagonists. Current treatment with disulfiram. More than 6 weeks of abstinence. Meets criteria for a major psychiatric disorder and is in need of, or currently undergoing pharmacotherapy.

All

NCT00000451

Inclusion Criteria: Alaska Native having biological Alaska Native ancestry. Meets criteria for alcohol dependence. Prior to entering the study must be abstinent between 3 and 14 days and have a withdrawal assessment. Stable residence to ensure that subjects can be located during the study. Exclusion Criteria: Currently meets criteria for abuse or dependence on substances other than alcohol or nicotine. Current use of disulfiram. Psychotic or otherwise severely psychiatrically disabled. Use of other psychotropic medications including antidepressants and anxiolytics. Medical conditions that would not permit the use of sertraline or naltrexone, such as a history of unstable or severe hepatic, cardiovascular, metabolic, endocrine, gastrointestinal or kidney disease. Hepatocellular disease or elevated bilirubin levels. Females who are pregnant, nursing, or not using a reliable method of birth control. Probation or parole requirements that might interfere with participation in the study. Involvement in alcohol treatment other than provided by the study or AA. Use of monoamine oxidase inhibitors in the past month. Current use of Type 1C antiarrhythmics propafenone and flecainide.

All

NCT00000452

Inclusion Criteria: Meets criteria for current diagnosis of alcohol dependence. Subjects used more than 15 standard alcohol drinks (average)/week with at least 1 day of 5 or more drinks in the past 30 days. Successful completion of medical detoxification. Lives within a commutable distance to the Treatment Research Center and agrees to follow-up visits. Understands and signs the informed consent. Exclusion Criteria: Current diagnosis of any substance dependence other than alcohol, nicotine, or marijuana. Evidence of opiate use in the past 30 days. Current treatment with psychotropic medications, including disulfiram (Antabuse) (excluding short-term use of benzodiazepines for detoxification). History of unstable or serious medical illness, including need for opioid analgesics. Severe physical or medical illnesses such as AIDS, active hepatitis, significant hepatocellular injury as evidenced by elevated bilirubin levels, and current severe psychiatric symptoms. Use of an investigation medication in the past 30 days. Female subjects who are pregnant, nursing, or not using reliable method of contraception.

All

NCT00000454

Inclusion Criteria: Meets criteria for alcohol dependence within the past three months, and criteria for nicotine dependence. Smoking at least 10 or more cigarettes per day for the past year. Seeking treatment for both alcohol and nicotine dependence. Minimum 1 week of alcohol abstinence and substance abuse day treatment attendance. Willing to provide names of two individuals who can help locate the subject at follow-up. Willing to provide name of one individual who can provide collateral information about alcohol and tobacco use. Exclusion Criteria: Other substance use disorder meeting criteria for dependence. Acute medical or psychiatric disorder requiring inpatient treatment. Taking medications known to influence alcohol urges (naltrexone, disulfiram). Medical problems that would contraindicate nicotine patch use. Allergy or hypersensitivity to nicotine or to adhesives used in transdermal delivery systems. Use of other nicotine products such as cigars, pipes, or smokeless tobacco. Severe generalized skin disorder. Myocardial infarction within 3 months prior to study entry. Unstable angina. Pregnant or lactating females, or females who are not practicing a medically accepted form of contraception. Impaired vision or hearing which would interfere with using a hand-held computer. Reading ability below fifth grade level. Lack of reliable transportation to the treatment site, or living more than 1 hour from treatment site. Homeless or unstable residence. Plan for future admission to residential treatment.

All

NCT00000455

Inclusion Criteria: Limited to early problem drinkers (i.e., those with no more than mild alcohol dependence). Have an average weekly alcohol consumption of greater than or equal to 24 standard drinks for men and 18 standard drinks for women. Able to read English at the eighth grade or higher level and show no evidence of significant cognitive impairment. Willing to provide a collateral informant for interviews regarding the patient's drinking during the study. A woman of child-bearing potential must be non-lactating, practicing a reliable method of birth control, and have a negative pregnancy test prior to initiation of treatment. Willing to provide a signed informed consent to participate in the study. Exclusion Criteria: Have a current clinically significant physical disease or abnormality. Have a serious psychiatric illness. Have a current diagnosis of drug dependence (other than nicotine dependence) or a lifetime diagnosis of opioid dependence. A current diagnosis of alcohol dependence that is moderate or greater in severity or a history of alcohol withdrawal, or recurrent use of alcohol to alleviate alcohol withdrawal symptoms. Used opioids or other psychoactive medications regularly in the month prior to study enrollment. History of hypersensitivity to naltrexone (Revia).

All

NCT00000456

Inclusion Criteria: Meets criteria for alcohol dependence, has not had more than one previous inpatient medical detoxification. Consumes on average five standard drinks per day. Able to maintain sobriety for five days (with or without the aid of detoxification medications) as determined by self-report, collateral report, and breathalyzer measurements. Able to read and understand questionnaires and informed consent. Lives within 50 miles of the study site. Exclusion Criteria: Currently meets criteria for any other psychoactive substance dependency disorder. Ever abused opiates. Used psychoactive substance abuse, except marijuana, within the last 30 days as evidenced by patient report, collateral report, and urine drug screen. Meets criteria for disorders of major depression, panic disorder, obsessive-compulsive disorder, post-traumatic stress syndrome, bipolar affective disorder, schizophrenia, or any other psychotic disorder or organic mental disorder. Meets criteria for dissociate disorder or eating disorders. Has current suicidal or homicidal ideation. Need for maintenance or acute treatment with any psychoactive medication including antiseizure medications. Current use of disulfiram (Antabuse). Clinically significant medical problems that would impair participation or limit medication ingestion. Hepatocellular disease. Sexually active females of child bearing potential who are pregnant, nursing, or who are not using a reliable form of birth control. Have current charges pending for a violent crime. Does not have a stable living situation and a reliable source of collateral reporting. Has taken an opiate antagonist drug in the last month.

All

NCT00000457

Inclusion Criteria: History of alcohol dependence and at least one year of abstinence from alcohol intake. Has a history of smoking 20 or more cigarettes per day for the prior year. Can read and write English. Stated ability to fully participate in the study and keep all scheduled appointments. Has provided written informed consent. General good health. Exclusion Criteria: Recent history (within three months) of a clinically significant myocardial infarction, unstable angina pectoris, serious cardiac arrhythmia or any other medical condition which the physician investigator deems incompatible with study participation. Current major depression. A past history of major depression will not be an exclusionary criteria. Current or previous use of bupropion (Wellbutrin). Active non- nicotine drug dependence. Past or current history of bipolar disorder, pain disorder or psychosis, schizophrenia, or other major psychiatric disorders. Current medically indicated use of psychiatric drugs. Females who are pregnant, lactating, or likely to become pregnant during the first year which includes the nicotine patch and bupropion (Wellbutrin) phase. History of severe skin allergies or evidence of severe chronic skin disorders. Current use of nicotine containing medication or tobacco products other than cigarettes. Current use (within 30 days of initiation of patch therapy) of the following medications for smoking cessation: clonidine, buspirone, or doxepin. A predisposition to seizures. A history of or current diagnosis of anorexia nervosa or bulimia. Medical disorder that would interfere with the absorption, metabolism, or excretion of bupropion (Wellbutrin).

All

NCT00000458

Inclusion Criteria: Meets criteria for major depressive episode. Meets criteria for alcohol abuse or dependence thirty days prior to entering the study. Has had no more than one previous inpatient medical detoxification. Able to maintain sobriety for ten days. Able to read and understand questionnaires and informed consent. Lives within 50 miles of the study site, has a stable living situation, and a reliable source of collateral reporting. Exclusion Criteria: Meets criteria for any other psychoactive substance dependence other than nicotine. Any psychoactive substance abuse (other than nicotine or marijuana) within 30 days before beginning of study. Meets criteria for other psychiatric disorders including: panic disorder, obsessive-compulsive disorder, bipolar affective disorder, cyclothymia, schizophrenia, any organic mental disorder, eating disorder, dissociative disorder, or post-traumatic stress disorder. Has evidence of treatment resistant depression defined as more than one previous treatment episode for depression, which can include hospitalization and/or one course of antidepressant medication. Patients may not have been prescribed a specific serotonergic medication within the month prior to study and may not have taken any antidepressant or antipsychotic within the two weeks prior to study. Current use of disulfiram (Antabuse) or anti-seizure medications. Clinically significant medical problems: cardiovascular, renal, gastrointestinal, or endocrine problems that would limit participation or limit medication ingestion. Hepatocellular disease. Females who are pregnant, nursing, or not using a reliable form of birth control. Current charges pending for violent crime (excluding DUI related offenses). Previous adverse experience with a serotonin reuptake inhibitor. Current homicidal or suicidal ideation.

All

NCT00000459

Children, ages 8 to 10, with elevated LDL-C levels.

All

NCT00000460

Men, ages 30 to 67, with documented coronary heart disease.

Male

NCT00000461

Men and women, normocholesterolemic, with 30 percent or greater narrowing of a coronary artery lumen as revealed by angiography. (Cholesterol-Lowering Agent Trial). Men and women with angiographically-documented coronary heart disease (Fish Oil Tr

All

NCT00000462

Multivessel coronary artery disease requiring revascularization and suitable for either PTCA or CABG.

All

NCT00000463

Men and women between 1 and 11 years post-CABG. Patients had two completely independent saphenous vein grafts that were patent. Patients had an LDL-cholesterol between 130 and 175 with plasma triglycerides below 300 mg/dl.

All

NCT00000464

Men and women with ventricular fibrillation who had survived an out-of-hospital cardiac arrest not associated with a Q-wave acute myocardial infarction.

All

NCT00000465

Men and women with multivessel coronary artery disease whose symptoms were refractory to medical treatment.

All

NCT00000466

Postmenopausal women, ages 45 to 64. One third of the subjects had had a hysterectomy.

Female

NCT00000467

Schools from the CATCH Trial (76) or schools unexposed to CATCH (12).

All

NCT00000468

Men and women, ages 35 to 71, with chest pain of between 15 minutes and 6 hours duration, systolic blood pressure of more than 80 mm Hg and less than 200 mm Hg, and a diastolic blood pressure of less than 120 mm Hg. (Phase I). Men and women with m

All

NCT00000469

Men and women with early carotid atherosclerosis and moderately elevated LDL cholesterol between the 60th and 90th percentiles.

All

NCT00000470

Boy and girl infants, up to three months of age, with transposition of the great arteries with or without septal defect.

All

NCT00000471

Men and women, ages 35 to 75, with angiographically documented one, two, or three vessel coronary disease; no myocardial infarction during the preceeding six weeks; and not receiving streptokinase, alteplase, or lipid-lowering drugs.

All

NCT00000472

Men and women, ages 21 to 76, with unstable angina or non-Q-wave myocardial infarction.

All

NCT00000473

Men and women with coronary heart disease in the native coronary arteries. Patients were symptomatic or had 50 percent or greater stenosis as defined by coronary angiography. Patients had not undergone prior angioplasty.

All

NCT00000474

Men and women with a diastolic blood pressure of 80 to 89 mm Hg and alcohol intake of 21 drinks or more per week.

All

NCT00000475

Men and women, ages 70 or older, with documented congestive heart failure.

All

NCT00000476

Men and women with clinical heart failure, sinus rhythm, and an ejection fraction less than or equal to 45 percent.

All

NCT00000477

Men and women, ages 65 and older, with elevated low-density lipoprotein cholesterol levels between 159 and 221 mg/dl at entry.

All

NCT00000478

Men aand women with angiographically documented coronary artery disease, ischemia on both stress (exercise) testing and 48-hour ambulatory electrocardiogram monitoring, and who were amenable to revascularization.

All

NCT00000479

Inclusion Criteria: Healthy women No previous history of cardiovascular disease or cancer No contraindications to aspirin or vitamin E

Female

NCT00000480

Men and women patients with documented coronary artery disease, ejection fraction less than or equal to 40 percent, and nonsustained asymptomatic ventricular tachycardia.

All

NCT00000481

Postmenopausal women, aged 50 to 69 years, who consumed 38 percent or more of total calories as fat at baseline.

Female

NCT00000482

Men, ages 30-64. Three months beyond most recent myocardial infarction.

Male

NCT00000484

Men and women, ages 21-55. Mild essential hypertension (diastolic blood pressure over 90 mm Hg.

All

NCT00000485

Men and women, ages 30-69. Hypertension. Diastolic blood pressure home readings and clinic readings equal to or above 95 mm Hg and 90 mm Hg, respectively.

All

NCT00000486

Men and women, ages 21 to 65. Angina pectoris (class III or class IV) at rest or with minimal exercise.

All

NCT00000487

Men, ages 35-57. One or more of three risk factors--hypertension, hypercholesterolemia, and cigarette smoking. Free from coronary heart disease.

Male

NCT00000488

Men, ages 35-59. Type II hyperlipoproteinemia. Free from coronary heart disease.

Male

NCT00000489

Men and women, under 67 years old. Ischemic heart disease.

All

NCT00000490

Men and women, ages 30 to 64. Had one myocardial infarction. Had hyperlipoproteinemia.

All

NCT00000491

Men and women, ages 30 to 69. Had a documented myocardial infarction.

All

NCT00000492

Men and women, ages 30 to 69. Documented myocardial infarction.

All

NCT00000493

Men and women, under age 75. Documented myocardial infarction which could be treated within 18 hours of onset of ischemic symptoms.

All

NCT00000494

Boy and girl premature infants with patent ductus arteriosus. Birth weight of 1,750 grams or less. Admitted to participating institution within first 24 hours of life.

All

NCT00000495

Men and women, ages 30 to 44. Normal high blood pressure of 80-89 mm Hg.

All

NCT00000496

Patients aged 65 or less. Angiographically identified coronary heart disease

All

NCT00000497

Men and women with hypertension. Diastolic blood pressure equal to or above 95 mm Hg and 90 mm Hg, respectively for home and clinic readings.

All

NCT00000498

Men and women with controlled hypertension.

All

NCT00000499

Men and women, aged 60 or over. Isolated systolic hypertension. Normal diastolic pressure of less than 90 mm Hg.

All

NCT00000500

Male physicians, ages 40 to 84. No history of stroke, myocardial infarction, cancer, or renal disease. No contraindications to aspirin or beta-carotene. No current usage of aspirin or Vitamin A tables greater than once per week.

Male

NCT00000501

Men and women, ages 25 to 49. Diastolic blood pressure between 78 and 89 mm Hg. Free of major disease. Not on a special diet or antihypertensive medication at entry. Some mild to moderately obese subjects.

All

NCT00000502

Men, women, and children in cardiac arrest for which CPR was initiated in ten minutes or less from the time of arrest.

All

NCT00000503

Men and women, under 78 years of age. Suspected of having an acute myocardial infarction and who could be randomized within 12 hours of onset of qualifying pain.

All

NCT00000504

Men and women. Patients had acute myocardial infarction and ventricular arrhythmias.

All

NCT00000505

Men and women under age 76. Patients had acute myocardial infarction.

All

NCT00000506

Men and women, ages 18 to 60. Body weight was 130 to 180 percent of ideal body weight.

All

NCT00000507

Men and women, aged less than 75. Myocardial infarction onset within six hours.

All

NCT00000508

Men and women, up to 75 years of age. Patients with coronary artery disease but no mechanical intervention on all major vessels.

All

NCT00000509

Men, ages 45 to 68. Subjects were hypertensive, were treated for at least 3.5 years with antihypertensive drugs and whose diastolic blood pressure was less than 90 mm Hg.

Male

NCT00000510

Patients to age 80 with angina pectoris.

All

NCT00000511

Mild hypertensives, ages 21 to 70, with no evidence of end-organ damage.. Untreated hypertensives.

All

NCT00000512

Inclusion Criteria: Men Age 62 or younger elevated apolipoprotein B levels coronary atherosclerosis family history of coronary heart disease. Exclusion Criteria: diabetes severe hypertension cancer liver disease thyroid disease kidney disease

Male

NCT00000513

Men and women, ages 21 to 65, with mild hypertension in the range of 90 to 100 mm Hg diastolic blood pressure. Subjects were obese (110-150 percent of ideal weight).

All

NCT00000514

Men and women, aged 60 or over, with isolated systolic hypertension.

All

NCT00000515

Men and women, ages 25 to 55. Subjects were obese, weighing between 130 and 210 percent of ideal body weight. Subjects had diastolic blood pressures between 90 and 105 mm Hg and were not on antihypertensive medications.

All

NCT00000516

Men and women, ages 21 to 80. Subjects were asymptomatic or symptomatic and had ejection fractions equal to or below 35 percent.

All

NCT00000517

Men and women, 18 years of age or older, with non-rheumatic atrial fibrillation.

All

NCT00000518

Men and women with documented ventricular tachycardia and those resuscitated from sudden death.

All

NCT00000519

Men and women, ages 25-49. Subjects were overweight with blood pressure less than 160/95 mm Hg and total cholesterol less than 260 mm/dl.

All

NCT00000520

Boys and girls who met the CDC criteria for Kawasaki Syndrome. Subjects were excluded if they presented themselves to the participating centers after the tenth day of illness.

All

NCT00000521

Children in grades 5 through 8 whose systolic blood pressure was greater than or equal to 120 mm Hg on two visits.

All

NCT00000522

Men and women, ages 45 to 69, with mild hypertension (diastolic blood pressure of 90-99 mm Hg at two of three visits for untreated individuals. Patients who received drug therapy must have had a DBP less than 95 mm Hg two to four weeks after drug.

All

NCT00000523

Sedentary men and women, ages 50 to 65. Women were postmenopausal and not taking hormone replacement therapy. All subjects were free from, but at increased risk for, coronary heart disease.

All

NCT00000524

Men and women, 18 years of age or older, with left ventricular failure and biopsy-documented myocarditis.

All

NCT00000525

Men, ages 35 to 70, with ECG abnormalities, diastolic blood pressure less than 95 mm Hg at entry. Subjects had been treated for at least six months by their own physicians with hydrochlorothiazide (HCT), HCT and potassium supplementation, triamteren

Male

NCT00000526

Men and women with ventricular premature depolarization six days to two years after the start of myocardial infarction.

All

NCT00000527

Men and women who had recently undergone carotid endarterectomy.

All

NCT00000528

Men and women, ages 30 to 54, with high normal diastolic blood pressure between 83 and 89 mm Hg. Subjects were mildly obese.

All

NCT00000529

Women over the age of 35 with a 5-year predicted breast cancer risk of at least 1.66 percent or a history of lobular breast carcinoma in situ, life expectancy of 10 years or more, breast examination and mammogram without evidence of cancer, no hormonal therapy within three months prior to randomization, and no history of deep venous thrombosis or pulmonary embolism. .

Female

NCT00000530

Men and women with documented primary or secondary Raynaud's syndrome.

All

NCT00000531

Men & women with VF, VT with syncope, or VT without syncope, but with ejection fraction less than or equal to .40 & systolic blood pressure less than 80 mm Hg, chest pain , or near syncope.

All

NCT00000532

Premenopausal women, ages 45-50 at entry.

Female

NCT00000533

Men and women myocardial infarction patients.

All